دورية أكاديمية
Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand–foot syndrome in cancer patients: a retrospective study
| العنوان: | Effectiveness of protocol-based pharmacotherapy management collaboration between hospital and community pharmacists to address capecitabine-related hand–foot syndrome in cancer patients: a retrospective study |
|---|---|
| المؤلفون: | Nobuhiko Nakamura, Hiroki Shiraiwa, Yasuhiro Haruna, Tomoki Ichijima, Tomoko Takeda, Koji Hasegawa, Masaaki Kusumoto, Yoshitaka Yano |
| المصدر: | Journal of Pharmaceutical Health Care and Sciences, Vol 7, Iss 1, Pp 1-7 (2021) |
| بيانات النشر: | BMC, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Therapeutics. Pharmacology LCC:Pharmacy and materia medica |
| مصطلحات موضوعية: | PBPM, Community pharmacists, Hospital pharmacists, Pharmaceutical care, Hand–foot syndrome, Capecitabine, Therapeutics. Pharmacology, RM1-950, Pharmacy and materia medica, RS1-441 |
| الوصف: | Abstract Background Pharmaceutical care of capecitabine-related hand–foot syndrome (HFS) is extremely important to avoid the progression of the syndrome. Protocol-based pharmacotherapy management (PBPM) of HFS by community pharmacists has been introduced in our community, whereby the community pharmacist instructs patients to use steroid creams if they develop HFS of grade 2 or higher. This study aimed to evaluate the effectiveness of PBPM in cancer patients with HFS by comparing it to conventional pharmaceutical care using monitoring reports for pharmacotherapy management by community pharmacists. Methods From September 2017 to August 2019, we retrospectively investigated the medical records of 396 cancer patients who received capecitabine adjuvant chemotherapy. Before PBPM implementation, conventional pharmaceutical care was administered from September 2017 to August 2018; these patients served as the control group. Care was switched to PBPM in September 2018, and PBPM was applied from September 2018 to August 2019; these patients served as the PBPM group. We excluded patients who received both conventional pharmaceutical care and PBPM. We categorized all cases into two groups: age ≤ 69 years and age ≥ 70 years. Results In all, 396 cases were included, of which 227 were ineligible, such as those of cancer patients who received both conventional pharmaceutical care and PBPM. Among patients aged higher than 70 years, the incidence and severity of HFS associated with PBPM were significantly lower than those associated with conventional care (grade 0: 59.5% [44/74] vs. 30.6% [11/36], grade 1: 33.8% [25/74] vs. 63.9% [23/36]). All patients continued to receive the capecitabine, HFS severity improved to grade 1 during the study period, and treatment of HFS was not stopped. Conclusion Our findings suggest that PBPM is effective for addressing capecitabine-related HFS among cancer patients aged higher than 70 years, in that it helps prevent an increase in HFS severity. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2055-0294 |
| العلاقة: | https://doaj.org/toc/2055-0294Test |
| DOI: | 10.1186/s40780-021-00191-1 |
| الوصول الحر: | https://doaj.org/article/a5e1101d24b049058d50d4577aa80423Test |
| رقم الانضمام: | edsdoj.5e1101d24b049058d50d4577aa80423 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 20550294 |
|---|---|
| DOI: | 10.1186/s40780-021-00191-1 |